GSK Plc
Open
$53.04
Prev. Close
$53.04
High
$53.07
Low
$52.99
Market Snapshot
$108.08B
13.8
1.60
$40.11B
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
Recently from Cashu
GSK Plc Acquires Nuvalent for $10.6 Billion to Enhance Oncology Portfolio and Precision Medicine
On June 10, 2026, GSK Plc (Ticker: GSK) announces its strategic acquisition of Nuvalent, Inc., a clinical-stage precision oncology firm, for $10.6 billion. This acquisition exemplifies GSK's commitmen…
U.S. Court Scrutinizes Vaccine Advisory Panel's Compliance with Federal Law and Public Health Governance
U.S. Government’s Vaccine Advisory Panel Actions Under Legal Scrutiny A federal court's recent commentary on the U.S. government's handling of vaccine recommendations signals a significant development…
GSK Expands Discounted Prescription Medications to Improve Accessibility and Affordability for Patients
GSK Expands Prescription Offerings, Enhancing Accessibility for Consumers GSK Plc makes significant strides in expanding its portfolio of discounted prescription medications, increasing the total numb…
GSK Expands Discounted Prescription Medications to Boost Accessibility and Affordability in Healthcare
GSK Expands Prescription Offerings to Enhance Accessibility and Affordability GSK Plc is poised to make significant advancements in the realm of affordable healthcare with its recent decision to expan…